Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ
Healthcare
Biotechnology
$612.50
▲ +0.42%
Market Cap
$63.10B
Sector
Healthcare
Industry
Biotechnology
Beta
0.24
52-Wk Range
514.79-821.11
CEO
Leonard S. Schleifer
Country
US
Currency
USD
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic derma…
Open full interactive analysis & DCF →